CA2212887A1 - Monoclonal antibody specific for .beta.a4 peptide - Google Patents

Monoclonal antibody specific for .beta.a4 peptide

Info

Publication number
CA2212887A1
CA2212887A1 CA002212887A CA2212887A CA2212887A1 CA 2212887 A1 CA2212887 A1 CA 2212887A1 CA 002212887 A CA002212887 A CA 002212887A CA 2212887 A CA2212887 A CA 2212887A CA 2212887 A1 CA2212887 A1 CA 2212887A1
Authority
CA
Canada
Prior art keywords
beta
peptide
instant invention
monoclonal antibody
antibody specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002212887A
Other languages
French (fr)
Other versions
CA2212887C (en
Inventor
Gerhard Konig
Paul Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23534218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2212887(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2212887A1 publication Critical patent/CA2212887A1/en
Application granted granted Critical
Publication of CA2212887C publication Critical patent/CA2212887C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The instant invention provides for monoclonal antibody which is specific for the .beta.A4 peptide, and in particular the free C-terminus of .beta.A4 "1-42" but not "1-43" and stains diffuse and fibrillar amyloid, vascular amyloid, and neurofibrillary tangles. The instant invention further provides for antibody fragments and constructs thereof which have the same binding specificity. The instant invention also provides for methods of diagnosis, screening and therapeutics for treating unique forms of .beta.A4 peptide, using the antibodies of the instant invention.
CA002212887A 1995-02-14 1996-02-14 Monoclonal antibody specific for .beta.a4 peptide Expired - Lifetime CA2212887C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/388,463 US5786180A (en) 1995-02-14 1995-02-14 Monoclonal antibody 369.2B specific for β A4 peptide
US08/388,463 1995-02-14
PCT/US1996/002491 WO1996025435A1 (en) 1995-02-14 1996-02-14 MONOCLONAL ANTIBODY SPECIFIC FOR βA4 PEPTIDE

Publications (2)

Publication Number Publication Date
CA2212887A1 true CA2212887A1 (en) 1996-08-22
CA2212887C CA2212887C (en) 2006-10-10

Family

ID=23534218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002212887A Expired - Lifetime CA2212887C (en) 1995-02-14 1996-02-14 Monoclonal antibody specific for .beta.a4 peptide

Country Status (11)

Country Link
US (3) US5786180A (en)
EP (3) EP1160256B2 (en)
JP (1) JP3115606B2 (en)
AT (2) ATE210681T1 (en)
CA (1) CA2212887C (en)
DE (2) DE69617916T2 (en)
DK (2) DK1160256T4 (en)
ES (3) ES2288896T5 (en)
HK (1) HK1114105A1 (en)
PT (2) PT809656E (en)
WO (1) WO1996025435A1 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
ATE402717T1 (en) 1997-04-09 2008-08-15 Intellect Neurosciences Inc RECOMBINANT ANTIBODIES SPECIFIC TO BETA-AMYLOID TERMS, DNA CODING THEREFOR, AND METHOD FOR USE THEREOF
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
ES2136535B1 (en) * 1997-04-15 2000-08-16 Consejo Superior Investigacion SYNTHETIC PEPTIDE FOR THE PRODUCTION OF ANTIBODIES AGAINST THE BETA AMYLOID PEPTIDE 1-42.
US7005295B1 (en) 1997-04-16 2006-02-28 Wyeth β-amyloid peptide-binding proteins and polynucleotides encoding the same
WO1998046636A2 (en) * 1997-04-16 1998-10-22 American Home Products Corporation β-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
AU2003262458B2 (en) * 1998-05-21 2008-06-19 University Of Tennessee Research Foundation Methods for amyloid removal using anti-amyloid antibodies
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
MXPA00011348A (en) 1998-05-21 2003-04-22 Univ Tennesse Res Corp Methods for amyloid removal using anti-amyloid antibodies.
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ES2312348T3 (en) * 1999-06-16 2009-03-01 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF LEVELS OF BETA-AMILOIDE IN VIVO.
TR200202799T3 (en) 2000-02-24 2003-03-21 Washington University St.Louis Humanized antibodies that sequence the AB peptide
WO2001077167A2 (en) * 2000-04-05 2001-10-18 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
JP2003516929A (en) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド Prevention and treatment of amyloidogenic diseases
CA2414772C (en) * 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en) * 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
DE60229051D1 (en) 2001-04-30 2008-11-06 Lilly Co Eli HUMANIZED ANTIBODIES
ES2437875T3 (en) 2001-04-30 2014-01-14 Eli Lilly And Company Humanized antibodies that recognize the beta-amyloid peptide
DK1944040T3 (en) 2001-08-17 2012-10-29 Univ Washington Method of analysis for Alzheimer's disease
JP2005519284A (en) * 2002-03-01 2005-06-30 アプレラ コーポレイション Determining the suitability of a set of chemical modifications for an amino acid chain
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040107871A1 (en) * 2002-08-09 2004-06-10 Defeo Maureen A. Aluminum trihydrate containing slurries
CA2501945A1 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
KR20050118669A (en) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 Active immunization to generate antibodies to soluble a-beta
ATE468886T1 (en) 2003-02-10 2010-06-15 Applied Molecular Evolution ABETA-BINDING MOLECULES
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EA016357B1 (en) * 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Antibodies directed against amyloid-beta peptide and methods using same
US20080199879A1 (en) * 2004-10-28 2008-08-21 Sanko Junyaku Co., Ltd. Method of Assaying Alzheimer's Disease and Diagnostic Reagent
JP2008519988A (en) * 2004-11-12 2008-06-12 ファイザー・インク Method for measuring amyloid-beta peptide
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
RU2007124933A (en) * 2005-01-28 2009-03-10 Вайет (Us) STABILIZED LIQUID POLYPEPTIDE COMPOSITIONS
GT200600031A (en) 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EA015148B1 (en) 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед METHODS OF PURIFYING Aβ BINDING PROTEIN HAVING A Fc REGION
RU2008120027A (en) * 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) ANTI-ADDL MONOCLONAL ANTIBODY AND ITS APPLICATION
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR101439828B1 (en) 2005-11-30 2014-09-17 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
RU2015111675A (en) * 2005-12-12 2015-08-10 Ац Иммуне Са SPECIFIC IN RESPECT TO AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES
RU2429244C2 (en) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Improved protofibril-selective antibodies and use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
KR101605207B1 (en) * 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. Humanized antibody against amyloid beta
FR2903999B1 (en) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc MODULATORS OF SC4MOL IN THE TREATMENT OF ACNE OR HYPERSEBORRHEA
US20100104577A1 (en) * 2006-10-10 2010-04-29 Golde Todd E Methods and materials related to anti-a (beta) antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2842967T (en) 2007-01-18 2017-01-13 Lilly Co Eli Pegylated amyloid beta fab
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2009445A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
DK2182983T3 (en) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES
EP2238166B1 (en) * 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RU2542967C2 (en) * 2007-10-05 2015-02-27 Дженентек, Инк. Using anti-amyloid beta antibody in ophthalmic diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
TW201223561A (en) 2010-10-26 2012-06-16 Ac Immune Sa Preparation of an antigenic construct
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
JP2012102131A (en) * 2012-01-05 2012-05-31 Elan Pharma Internatl Ltd Prophylaxis and treatment for amyloidogenic disease
CN103665113A (en) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 Human A beta 42 antigenic determinant polypeptide, human A beta 42 antigen, human A beta 42 antibody, application and kit
KR102308915B1 (en) 2012-10-15 2021-10-06 메디뮨 리미티드 Antibodies to amyloid beta
JP2016103980A (en) * 2013-03-08 2016-06-09 パナソニックヘルスケア株式会社 Hybridoma and monoclonal antibody
KR20230129449A (en) 2014-07-10 2023-09-08 바이오악틱 에이비 Improved Aβ Protofibril Binding Antibodies
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0527823A1 (en) * 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
DE69432629T3 (en) * 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. ANTIBODIES AGAINST BETA AMYLOID OR DERIVATIVES AND ITS USE

Also Published As

Publication number Publication date
JP3115606B2 (en) 2000-12-11
EP1160256B1 (en) 2007-06-27
EP0809656A1 (en) 1997-12-03
ATE365750T1 (en) 2007-07-15
EP1842859A2 (en) 2007-10-10
US5693753A (en) 1997-12-02
HK1114105A1 (en) 2008-10-24
ES2288896T3 (en) 2008-02-01
US5786180A (en) 1998-07-28
DK1160256T3 (en) 2007-10-22
CA2212887C (en) 2006-10-10
DK0809656T3 (en) 2002-03-18
PT1160256E (en) 2007-10-08
EP0809656B1 (en) 2001-12-12
EP1160256B8 (en) 2009-04-01
EP1842859A3 (en) 2007-11-28
DK1160256T4 (en) 2012-01-09
DE69637150D1 (en) 2007-08-09
MX9706189A (en) 1997-11-29
DE69617916D1 (en) 2002-01-24
US5679531A (en) 1997-10-21
DE69637150T2 (en) 2008-02-28
PT809656E (en) 2002-06-28
EP1842859B1 (en) 2013-01-09
ES2288896T5 (en) 2012-02-16
DE69617916T2 (en) 2002-05-16
ATE210681T1 (en) 2001-12-15
ES2400674T3 (en) 2013-04-11
EP1160256A2 (en) 2001-12-05
EP1160256A3 (en) 2002-11-06
WO1996025435A1 (en) 1996-08-22
JPH10509736A (en) 1998-09-22
DE69637150T3 (en) 2012-03-15
ES2167548T3 (en) 2002-05-16
EP1160256B2 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
CA2212887A1 (en) Monoclonal antibody specific for .beta.a4 peptide
PL330075A1 (en) Antibodies against the ed-b domain of fibronectin, their construction and application
WO2003039467A3 (en) Monoclonal antibodies specific for beta-amyloid.
EP0852011A4 (en) ANTIBODIES SPECIFIC FOR NATIVE PrP?Sc
HUP9904052A3 (en) Monoclonal antibodies againts the extracellular domain of human vegf-receptor protein (kdr)
EP0724456A4 (en) Antibodies to cd40
EP0870826A4 (en) Novel protein and monoclonal antibody specific thereto
ES8802457A1 (en) Ras oncogene peptides and antibodies.
CA2068222A1 (en) Monoclonal antibodies
EP0871661A4 (en) Novel protein domain which binds tyrosine phosphorylated proteins
CA2071211A1 (en) Immunoassays for and monoclonal antibodies to prothrombin activation peptides and their degradation products
AU5508396A (en) Pcna binding substance
EP0725081A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN Mx PROTEIN MxA
AU3455693A (en) Peptides of the casein macropeptide, antibodies directed against said peptides, and applications
PL323195A1 (en) Alpha unit of human integrin beta 2
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
HUP0003029A2 (en) Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same
GB2333295A (en) Modified protein G and fragments thereof
AU2525597A (en) Monoclonal antibodies binding human growth hormone (hgh)
HUP9902836A2 (en) Methods for determining the presence of brain protein s-100
WO2001046419A3 (en) Mammalian prion proteins; related reagents and methods

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160215